Mercy BioAnalytics
Mercy BioAnalytics, Inc. is a leader in the development of extracellular vesicle-based liquid biopsies aimed at the early detection of cancer. The company’s patented Mercy Halo™ platform leverages biomarker co-localization to analyze blood-based extracellular vesicles, which carry unique cancer signatures, to identify early-stage cancers when they are most treatable. Initially focusing on ovarian and lung cancers, Mercy BioAnalytics is committed to enhancing early cancer detection to improve patient outcomes and quality of life.
Leadership & Board
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $59M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $59M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 03, 2025 | Series B | $59.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Portfolia | Series B |
| Labcorp | Series B |
| Sozo Ventures | Series B |
| Perceptive Xontogeny Venture Fund | Series B |
| Novalis | Series B |
| American Cancer Society BrightEdge | Series B |
| iSelect Fund | Series B |
| Avestria Ventures | Series B |
Similar Companies
A snapshot of private companies similar to Mercy BioAnalytics, helping you discover and navigate related company profiles.
Related News and Analysis
